Hence then, the article about essa pharma announces termination of phase 2 study evaluating masofaniten combined with enzalutamide in patients with metastatic castration resistant prostate cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer )
Last updated :
Also on site :
- Atalanta vs Parma: How to Watch Live, Match Time and TV Channels
- Carnival Adds Massive ‘Cat in the Hat’ Character Fun Across 23 Cruise Ships
- What time do polls open and close in Illinois? 2026 Election Day voting guide